10 recruiting, 8 active not recruiting, 8 not yet recruiting, 1 completed. 13 Phase 3, 12 Phase 1, 2 Phase 2.
Follow Gan & Lee Pharmaceuticals.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of GLR1075 Injection in Healthy Trial Participants and Cirrhotic Trial Participants With Ascites and Hypoalbuminemia placebo GLR1075 Vehicle, Human Serum Albumin(HSA), GLR1075 Injection - Hypoalbuminemia in Cirrhotic Ascites | Phase 1 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 106 | 2026-10-07 | 2026-10-01 |
| A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants GZC8072 Tablets, Placebo - Healthy Subjects;Overweight or Obesity | Phase 1 | Recruiting | Gan & Lee Pharmaceuticals. | 126 | 2026-09-02 | 2026-09-30 |
| Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants GZR4 injection A, GZR4 injection B - T2D | Phase 1 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 64 | 2026-07-01 | 2026-06-26 |
| A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer GLR2037 - Prostate Cancer | Phase 1 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 65 | 2026-04-30 | 2026-03-12 |
| Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy Placebo, GZR18 injection - Obstructive Sleep Apnea (OSA) | Phase 3 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 140 | 2026-04-27 | 2026-03-27 |
| Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes GZR101-80, GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30) - Type 2 Diabetes (T2DM) | Phase 2 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 345 | 2026-04-10 | 2026-04-15 |
| Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes GZR33 Injection, Insulin Degludec Injection (Tresiba®) - Type 2 Diabetes (T2DM) | Phase 3 | Recruiting | Gan & Lee Pharmaceuticals. | 350 | 2026-04-07 | 2026-07-01 |
| Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy GZR18 injection, Placebo - Obstructive Sleep Apnea (OSA) | Phase 3 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 140 | 2026-03-27 | 2026-04-03 |
| A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects GLR1044 injection, Dupilumab Injection - Biosimilarity | Phase 1 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 198 | 2026-03-09 | 2026-01-12 |
| Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss GZR18 injection, Placebo - Overweight or Obesity | Phase 3 | Recruiting | Gan & Lee Pharmaceuticals. | 500 | 2026-01-22 | 2026-03-11 |
| Bioequivalence Study of GZR18 Injection Before and After CMC Change GZR18 injection A, GZR18 injection B - Obesity&T2D | Phase 1 | Recruiting | Gan & Lee Pharmaceuticals. | 138 | 2026-01-09 | 2026-01-22 |
| Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets - Obesity or Overweight | Phase 1 | Recruiting | Gan & Lee Pharmaceuticals. | 60 | 2025-11-17 | 2025-12-12 |
| Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment GZR4 - Diabetes | Phase 1 | Active not recruiting | Gan & Lee Pharmaceuticals. | 36 | 2025-10-20 | 2025-11-28 |
| A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin GZR4, Insulin Icodec group - Diabetes | Phase 3 | Recruiting | Gan & Lee Pharmaceuticals. | 300 | 2025-10-17 | 2025-11-25 |
| Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects GZR18, Semaglutide(Wegovy® ) - Obesity/Overweight in Adult | Phase 3 | Recruiting | Gan & Lee Pharmaceuticals. | 420 | 2025-09-23 | 2025-11-25 |
| Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function GZR18 injection - Obesity/Overweight | Phase 1 | Recruiting | Gan & Lee Pharmaceuticals. | 24 | 2025-08-12 | 2025-08-27 |
| A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus GZR102, GZR18 - Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Active not recruiting | Gan & Lee Pharmaceuticals. | 90 | 2025-08-07 | 2025-11-21 |
| A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects GZR102 injection, GZR4 injection, GZR18 injection - Type 2 Diabetes | Phase 1 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 30 | 2025-05-08 | 2025-05-16 |
| The Study of [14C] GZR18 GZR18 injection、[14C]GZR18 injection - Overweight, Obese | Phase 1 | Completed | Gan & Lee Pharmaceuticals. | 6 | 2025-05-07 | 2025-11-21 |
| Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function GZR18 injection - Obesity/Overweight | Phase 1 | Recruiting | Gan & Lee Pharmaceuticals. | 32 | 2025-04-11 | 2025-11-21 |
Showing 20 of 27. Sign in to see all of them.
Obesity (9) · Diabetes Mellitus, Type 2 (6) · Overweight (6) · Diabetes Mellitus (5) · Insulin Resistance (3) · Sleep Apnea, Obstructive (2) · Hyperlipidemias (1) · Hypoalbuminemia (1) · Prostatic Neoplasms (1)
insulin degludec (3) · semaglutide (2) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (1) · Insulin Aspart (1) · Rosuvastatin Calcium (1) · Serum Albumin, Human (1) · Warfarin (1) · dupilumab (1)
China (27)
Liyuan Zhao Ph.D (1)